Muromonab-CD3-induced neurotoxicity: Report of two siblings, one of whom had subsequent cyclosporin-induced neurotoxicity

Journal of Child Neurology

Volumn 16, Issue 11, 2001, Pages 825-831

  Thaisetthawatkul, P ^a   Weinstock, A ^a   Kerr, S L ^a   Cohen, M E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CEFTRIAXONE; CORTICOSTEROID; CYCLOSPORIN; CYTOKINE; GABAPENTIN; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PHENOBARBITAL; PREDNISONE; VIRUS ANTIBODY;

ADOLESCENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN DISEASE; CASE REPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOENCEPHALOPATHY; LYMPHOCYTE ACTIVATION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; PARESIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCHOOL CHILD; SEIZURE; SIBLING; WHITE MATTER;

EID: 0035218384     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738010160110801     Document Type: Article

References (35)

1. Muromonab-CD3 and antithymocyte globulin in renal transplantation
2. Ten years of Orthoclone OKT3 (muromonab-CD3): A review
3. Generalized seizures associated with the use of muromonab-CD3 in two patients after kidney transplantation
4. Encephalopathy associated with muromonab-CD3
5. Seizures and cerebritis associated with administration of OKT3
6. OKT3 encephalopathy
7. Nosocomial aseptic meningitis associated with administration of OKT3
8. Optic disc swelling and abducens palsies associated with OKT3
9. Visual loss complicating OKT3 monoclonal antibody therapy
10. Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3
11. Cerebral complications of murine monoclonal CD3 antibody (OKT3): CT and MRI findings
12. Cyclosporin A acute encephalopathy and seizure syndrome in childhood: Clinical features and risk of seizure recurrence
13. Cytokine-related encephalopathy induced by OKT3: Incidence and predisposing factors
14. Encephalopathy following the use of OKT3 in renal allograft transplantation
15. Monitoring and complications of monoclonal therapy
16. In vivo cell activation following OKT3 administration: Systemic cytokine release and modulation by corticosteroids
17. T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies
18. Anti-CD3 antibody induces rapid expression of cytokine genes in vivo
19. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3
20. IL-2 activated human killer lymphocytes but not their secreted products mediate increase in albumin flux across cultured endothelial monolayers
21. Evaluation of recombinant human soluble dimeric tumor necrosis factor for prevention of OKT3-associated acute clinical syndrome
22. Major histocompatibility complex regulation of cytokine production
23. A reversible posterior leucoencephalopathy syndrome
24. MR imaging of reversible cyclosporin A-induced neurotoxicity
25. Disturbance of blood-brain barrier after bone marrow transplantation
26. Cyclosporine neurotoxicity
27. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells
28. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation
29. Renal vascular and thrombotic effects of cyclosporine
30. Cortical hypersensitivity on proton-weighted images: An MR sign of cyclosporine-related encephalopathy
31. Neurologic complications of FK506
32. Posterior leucoencephalopathy syndrome
33. Cyclosporin neurotoxicity after chemotherapy
34. Cyclosporin metabolities and central nervous system toxicity
35. Central nervous system toxicity after liver transplantation: The role of cyclosporine and cholesterol